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Stereologically estimated mean nuclear volume of
prostatic cancer is a reliable prognostic parameter
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Summary Although different histological grading systems of prostatic cancer refer to well-described characteristics, results are hard to
reproduce. The aim of this study was to obtain morphometric data that would enable objective and reproducible grading of prostatic cancers
by stereological estimation of mean nuclear volume (MNV). The clinical records and tissue specimens from 100 patients who were newly
diagnosed as having prostatic cancer from 1973 to 1990 and who were followed up for 5 years or longer were retrospectively examined. We
analysed the relationship between MNV and clinical stage, Gleason score and histological grading according to the World Health
Organization (WHO) classification. To evaluate prognostic predictors, a multivariate analysis of factors associated with cause-specific survival
was performed. We found a good correlation between the MNV and clinical stage and between the MNV and histological grading. There was
no correlation between MNVs and Gleason scores. Multivariate analysis revealed that the MNV was the only predictor of survival time
(coefficient 0.005; P < 0.0001; hazard ratio 1.005). We consider that the MNV is an excellent predictor of the prognosis in patients with
prostatic cancer. Moreover, stereological estimation of MNV is a simple, quick, inexpensive and reliable morphometric procedure that enables
the quantitative analysis of the histological and biological character of prostatic cancer.
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Most grading systems of prostatic cancer are based on the pattern
ofhistological growth and on the cytological appearance. Although
all systems refer to well-described characteristics, evaluation of
findings is subjective and therefore results are hard toreproduce. In
the past few years, some quantitative grading techniques have been
introduced (Partin et al, 1992; Song et al, 1992). However, no
optimal morphometrical procedure to express the histological and
biological character ofprostatic cancer has been established so far.
The aim of this study was to obtain morphometric data that would
enable objective and reproducible grading of prostatic cancers by
stereological estimation of mean nuclear volume (MNV). This
method is based on the principle of unbiased estimation of the
volume of particles of arbitrary shape, as described by Gundersen
and Jensen (1985). This estimation depends on simple and efficient
point sampling oflinear intercept length.
Using this method, we performed a study to compare nuclear
volume measurements with histological grading with respect to
prognostic impact.
MATERIALS AND METHODS
Patients and histological samples
This study was a retrospective evaluation of 100 patients who
were newly diagnosed as having prostatic cancer from 1973 to
1990 and who were followed up for 5 years or longer at the Mie
University Hospital, in Mie, Japan.
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The clinical stages were Al (n = 2), A2 (n = 4), BI (n = 5), B2
(n = 7), C (n = 32), Dl (n = 1) and D2 (n = 49). The staging was
performed according to the Whitmore-Jewett system. All patients
except those with stage Al prostate cancer were treated with
diethylstilboestrol diphosphate, in addition to castration in 18
patients and radiation in six; when the tumour became refractory
to hormonal therapy, symptomatic therapy was given.
Histological samples were taken from needle biopsy or
transurethral resection of the prostate before any treatment was
given. The tissue specimens were immediately fixed in 10%
formalin at room temperature for about 24 h, embedded in paraffin
and sectioned at 4 mm thickness. For histopathological examina-
tion, the sections were stained with haematoxylin-eosin.
Gleason score and histological grading according to the general
rules for clinical and pathological studies on prostatic cancer,
which were established by the Japanese Urological Association
based on the WHO classification, were determined by a
histopathologist who was unfamiliar with the clinical outcome.
Morphometric methods
An Olympus microscope (Olympus, Tokyo, Japan) was equipped
with a projection attachment. Using this system with a 100x
immersion oil lens, the fields of vision were projected onto a
surface. The absolute magnification was 1800x. Areas showing
the most pronounced lack of differentiation were selected for the
tumour field. The lengths of the intercepts through test points
hitting a nucleus were classified using the modified Vlo3 ruler
(Brandgaard et al, 1986). The mean intercept (length)3, Vbl3,
multiplied by n/3 is an unbiased estimate of the volume
of nuclei sampled with a chance proportional to their volume:
Vv = n/3 * Vlo3. The subscript v indicates that the nuclei are
sampled with a chance proportional to the individual volume; the
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mean volume is therefore volume weighted. The average number
ofpoint-sampled intercepts per tumour was 80, and the collection
ofthis set of data required less than 20 min per tumour. It is note-
worthy that no assumptions need to be made about the shape ofthe
nucleus (Gundersen et al, 1985).
Statistics
Differences among the groups were analysed using the Student's
paired t-test with Welch's correction. The prognostic effect of
interval to disease-specific death for the quantitative parameters
was studied using the generalized Wilcoxon test and illustrated by
Kaplan-Meier plots. To evaluate prognostic factors, multivariate
analysis of factors associated with cause-specific survival was
performed using Statview software based on the Cox proportional
hazards model. The level ofsignificance for all tests was P < 0.05.
RESULTS
The range and mean ± s.d. of MNV according to clinical stage
were 183.6-454.3 jim3 and 250.4 ± 76.5 jm3 for A and B (n = 18)
and 80.9 -782.0 ,um3 and 350.0 ± 134.2 jm3 for C and D (n = 82).
The MNV was significantly larger in patients with advanced-stage
Figure 3 Kaplan-Meier curves for disease-specific survival according to
estimates of MNV
prostatic cancer than in those with early-stage prostatic cancer
(P < 0.01; Figure 1).
The 100 patients were classified as having well (n = 21), moder-
ately (n = 41) and poorly (n = 38) differentiated adenocarcinoma
according to the WHO classification. The range and mean ± s.d. of
MNV were 80.9-534.7 jim3 and 287.9 ± 76.5 jm3 for well-differ-
entiated adenocarcinoma, 187.7-689.7 jm3 and 315.3 ± 147.2 jm3
for moderately differentiated adenocarcinoma and 145.7-
782.0 jim3 and 393.8 ± 132.3 jim3 for poorly differentiated adeno-
carcinoma. The MNV was significantly larger in patients with
poorly differentiated prostatic cancer than in those with well-
differentiated prostatic cancer (P < 0.01, Figure 2).
Patients were divided into two subgroups, one group with aMNV
above 257 jm3 (n = 65) and the other with a MNV below this value
(n = 35), which was the average value ofMNV for prostatic cancer.
The cause-specific survival curve ofthe two subgroups is shown in
Figure 3. Patients with a MNV below 257 jm3 had a significantly
betterprognosis than those with a MNV above this value (P < 0.01).
The 5- and 10-year survival rates for patients with a MNV below
257 jm3 were 66.1% and 33.7%, while those for patients with a
MNV above 257 jm3 were 23.9% and 12.3% respectively. Survival
rates for patients with small nuclei were significantly better than
those forpatients with large nuclei (P < 0.01).
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Because recent studies have shown that a Gleason score of 7 or
higher indicates a high-grade tumour (Epstein et al, 1993), patients
were divided into two subgroups: one group with aGleason score of
7 or higher (n = 35) and the other with a Gleason score of 6 or less
(n = 65). The cause-specific survival curves of the two subgroups
did not differ significantly. There was no correlation between MNVs
and Gleason scores (correlation coefficient = 0.0344; Figure 4).
To find factors contributing to survival time, multivariate
analysis was performed for Gleason score, WHO classification
and MNV. The results of this analysis suggest that MNV was
the only factor associated with survival time: coefficient 0.005;
P < 0.0001; hazard ratio 1.005; and 95% confidence interval
1.003, 1.007 (Table 1).
DISCUSSION
The Gleason score is used to determine the degree of malignancy
of prostatic cancer and to predict prognosis. The Gleason score is
based on assessment of the architectural pattern of the tumour,
ignoring cytological features. However, as the evaluation is
subjective, results are difficult to reproduce. Gleason estimated the
intra-observer reproducibility rate to be 80% (Cintra et al, 1991),
although other investigators reported it to be 42-65% (Svanholm
et al, 1985). Bocking et al (1982) reported that their grading
system had higher reproducibility than that of Gleason score; but
their system is also subjective. The measurement ofcell character-
istics provides a more objective method for tumour grading. Song
et al (1992) demonstrated that flow cytometry was superior to the
conventional prostatic cancer nuclear grading system in predicting
prognosis. DNA analysis, such as flow cytometry, is certainly an
objective method, but a problem with routine application of DNA
flow cytometry is the chance of contamination of tumour nuclei
with benign nuclei. Partin et al (1992) demonstrated that a
computer-based nuclear morphometry system, such as a nuclear
shape descriptor, could add to the prognostic information provided
by the Gleason score system. However, the computer-based
nuclear morphometry system is slightly cumbersome; and as
tissues, cells and nuclei have three-dimensional structures, it
seems logical to estimate nuclear enlargement in terms of volume.
The study ofGundersen and Jensen (1985) has made it possible to
Table 1 Multivariate analysis of factors associated with disease-specific
survival on the Cox proportional hazards model
Variable Coefficient P-value Hazard ratio 95% Cl
Gleason score 0.294 0.0636 1.342 0.983, 1.830
WHO classification
Poorly v moderately -0.029 0.9241 0.972 0.540,1.750
Poorly v well -0.361 0.5275 0.697 0.227, 2.136
MNV 0.005 < 0.0001 1.005 1.003, 1.007
Cl, confidence interval.
estimate the mean volume of particles of arbitrary shape. They
made an unbiased estimate of the mean volume of nuclei sampled
with a chance proportional to their volume: Vv = n/3* Vlo3. Here,
lo is the length of the intercept through a test point hitting a
nucleus measured in a random direction. Using this 'Point
Sampled Intercepts' method, Nielsen et al (1986) found a very
good correlation between the mean nuclear volume in bladder
tumours and prognosis. In prostatic cancer also, the same tendency
has been seen (Fujikawa et al, 1995a).
Recent advances in the field of molecular biology offer a
number ofmarkers representing the biological character of cancer
cells. In bladder tumours, the MNV and DNA content determined
by flow cytometry showed a significant correlation (Nielsen et al,
1989a). It could be expected that the larger the nuclei the greater
the DNA content. However, it should be noted that this correlation
was far from being perfectly linear. This indicates that the MNV is
more than a simple reflection ofthe DNA content. There might be
a relation between the MNV and the activity of the DNA, i.e. the
amount of active DNA (euchromatin) and inactive DNA (hetero-
chromatin), and the nuclear amount of RNA. Cell cycle kinetics
might also influence the MNV, as a correlation between the MNV
and the percentage of cells in different phases may exist, i.e. a
tumour with many cells in the Go phase with diploid DNA content
and few cells in the G2/M-phase with tetraploid DNA content may
have a smaller MNV than a tumour with few cells in the Go phase
and many cells in the G2/M-phase.
Nielsen et al (1989b) compared the MNV of the tumour at the
repeated transurethral resection ofprostatic cancer with that at the
first transurethral resection ofprimary cancer, and the former was
significantly increased compared with the latter. We reported that
the MNV ofrecurrent bladder tumours was significantly increased
compared with the MNV ofprimary tumours (Arima et al, 1993).
It seemed that the increase of MNV was related to aggressive
tumour behavior.
The MNV oftumours examined in the present study was spread
over a wide range, from 80.9 tm3 to 782.0 tm3, and was not so
different from that reported by other authors (Jorgensen et al, 1988;
Fujikawa et al, 1995a). We found a good correlation between the
MNV in prostatic cancers and clinical stage and between the MNV
and WHO classification. Kaplan-Meier curves for disease-specific
survival showed that MNV was more useful than the Gleason score
as a prognostic factor for prostatic cancer. Fujikawa et al (1995b)
also observed that the MNV was a more useful prognostic indicator
for disease-specific survival in stage D2 prostatic cancer and for
progression-free survival in clinically localized prostatic cancer
than subjective histological grades. They did not find a good corre-
lation between the MNV in prostatic cancers and clinical stage or
between the MNV and the WHO classification. However, they and
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we have shown that the prognosis ofpatients with tumours demon-
strating a larger MNV was significantly poorer, and multivariate
analysis revealed that MNV was the only predictor of survival
time. Furthermore, it is important to note that stereological estima-
tion of the mean nuclear volume is a simple, quick, inexpensive
and reliable method. Further prospective studies with a much
larger number of subjects are needed to establish the relationship
between MNV and prognosis.
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